Temasek cashed out part of its investment in South Korean biopharmaceutical firm Celltrion and its affiliate Celltrion Healthcare for a combined W1.07 trillion ($994 million) on Tuesday, as the Singaporean sovereign wealth fund continues to reshape its portfolio to address long-term opportunities.
¬ Haymarket Media Limited. All rights reserved.
